{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:49:40Z","timestamp":1782276580162,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"DOI":"10.7759\/cureus.111393","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:43:57Z","timestamp":1782276237000},"source":"Crossref","is-referenced-by-count":0,"title":["Myo-Inositol for Cutaneous Manifestations of Polycystic Ovary Syndrome: An International Delphi Consensus Recommendation for Dermatology Practice"],"prefix":"10.7759","author":[{"given":"Anil","family":"Ganjoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malavika","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajetha","family":"Damisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Kandhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balram","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilakshi","family":"Deka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Beatrice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambika  R","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudip","family":"Parajuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haikal  A","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarker Mahbub  A","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathish","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratik","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish R","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012608","article-title":"Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: a population-based cohort study in Taiwan","volume":"97","author":"Ding DC","year":"2018","unstructured":"Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: a population-based cohort study in Taiwan. Medicine (Baltimore). 2018, 97:e12608. 10.1097\/MD.0000000000012608","journal-title":"Medicine (Baltimore)"},{"key":"ref2","unstructured":"Polycystic ovary syndrome. (2025). Accessed. February 7, 2025: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/polycystic-ovary-syndrome."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.40583","article-title":"Prevalence, phenotypes, and comorbidities of polycystic ovary syndrome among Indian women","volume":"7","author":"Ganie MA","year":"2024","unstructured":"Ganie MA, Chowdhury S, Malhotra N, et al.. Prevalence, phenotypes, and comorbidities of polycystic ovary syndrome among Indian women. JAMA Netw Open. 2024, 7:e2440583. 10.1001\/jamanetworkopen.2024.40583","journal-title":"JAMA Netw Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/2229-5178.202275","article-title":"Cutaneous manifestations of polycystic ovary syndrome: a cross-sectional clinical study","volume":"8","author":"Keen MA","year":"2017","unstructured":"Keen MA, Shah IH, Sheikh G. Cutaneous manifestations of polycystic ovary syndrome: a cross-sectional clinical study. Indian Dermatol Online J. 2017, 8:104-10. 10.4103\/2229-5178.202275","journal-title":"Indian Dermatol Online J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2020.1859474","article-title":"Prevalence of acne vulgaris among women with polycystic ovary syndrome: a\u00a0systemic review and meta-analysis","volume":"37","author":"Ramezani Tehrani F","year":"2021","unstructured":"Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi Yarandi R, Saei Ghare Naz M, Carmina E. Prevalence of acne vulgaris among women with polycystic ovary syndrome: a\u00a0systemic review and meta-analysis. Gynecol Endocrinol. 2021, 37:392-405. 10.1080\/09513590.2020.1859474","journal-title":"Gynecol Endocrinol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2004.05.007","article-title":"Hirsutism and acne in polycystic ovary syndrome","volume":"18","author":"Archer JS","year":"2004","unstructured":"Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004, 18:737-54. 10.1016\/j.bpobgyn.2004.05.007","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2023-000548","article-title":"Polycystic ovary syndrome: pathophysiology and therapeutic opportunities","volume":"2","author":"Dong J","year":"2023","unstructured":"Dong J, Rees DA. Polycystic ovary syndrome: pathophysiology and therapeutic opportunities. BMJ Med. 2023, 2:e000548. 10.1136\/bmjmed-2023-000548","journal-title":"BMJ Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.007","article-title":"Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations","volume":"71","author":"Housman E","year":"2014","unstructured":"Housman E, Reynolds RV. Polycystic ovary syndrome: a review for dermatologists: Part I. Diagnosis and manifestations. J Am Acad Dermatol. 2014, 71:847.e1-847.e10. 10.1016\/j.jaad.2014.05.007","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2004.03.010","article-title":"Acne: hormonal concepts and therapy","volume":"22","author":"Thiboutot D","year":"2004","unstructured":"Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004, 22:419-28. 10.1016\/j.clindermatol.2004.03.010","journal-title":"Clin Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp033496","article-title":"Clinical practice. Hirsutism","volume":"353","author":"Rosenfield RL","year":"2005","unstructured":"Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005, 353:2578-88. 10.1056\/NEJMcp033496","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"108","author":"Teede HJ","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJ, et al.. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023, 108:2447-69. 10.1210\/clinem\/dgad463","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biochi.2013.05.011","article-title":"Potential role and therapeutic interests of myo-inositol in metabolic diseases","volume":"95","author":"Croze ML","year":"2013","unstructured":"Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013, 95:1811-27. 10.1016\/j.biochi.2013.05.011","journal-title":"Biochimie"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/09513590801893232","article-title":"Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome","volume":"24","author":"Genazzani AD","year":"2008","unstructured":"Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol. 2008, 24:139-44. 10.1080\/09513590801893232","journal-title":"Gynecol Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7019126","article-title":"Efficacy and safety of Tracnil\u2122 administration in patients with dermatological manifestations of PCOS: an open-label single-arm study","volume":"2020","author":"Ramanan EA","year":"2020","unstructured":"Ramanan EA, Ravi S, Anbu KR, Michael M. Efficacy and safety of Tracnil\u2122 administration in patients with dermatological manifestations of PCOS: an open-label single-arm study. Dermatol Res Pract. 2020, 2020:7019126. 10.1155\/2020\/7019126","journal-title":"Dermatol Res Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/09513590903015544","article-title":"Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome","volume":"25","author":"Zacch\u00e8 MM","year":"2009","unstructured":"Zacch\u00e8 MM, Caputo L, Filippis S, Zacch\u00e8 G, Dindelli M, Ferrari A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol. 2009, 25:508-13. 10.1080\/09513590903015544","journal-title":"Gynecol Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1849162","article-title":"Effects of Inositol(s) in women with PCOS: a systematic review of randomized controlled trials","volume":"2016","author":"Unfer V","year":"2016","unstructured":"Unfer V, Nestler JE, Kamenov ZA, Prapas N, Facchinetti F. Effects of Inositol(s) in women with PCOS: a systematic review of randomized controlled trials. Int J Endocrinol. 2016, 2016:1849162. 10.1155\/2016\/1849162","journal-title":"Int J Endocrinol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1530\/EC-17-0243","article-title":"Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials","volume":"6","author":"Unfer V","year":"2017","unstructured":"Unfer V, Facchinetti F, Orr\u00f9 B, Giordani B, Nestler J. Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocr Connect. 2017, 6:647-58. 10.1530\/EC-17-0243","journal-title":"Endocr Connect"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.14754","article-title":"Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials","volume":"125","author":"Pundir J","year":"2018","unstructured":"Pundir J, Psaroudakis D, Savnur P, et al.. Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials. BJOG. 2018, 125:299-308. 10.1111\/1471-0528.14754","journal-title":"BJOG"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-024-02363-w","article-title":"Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology","volume":"47","author":"Moretti C","year":"2024","unstructured":"Moretti C, Bonomi M, Dionese P, et al.. Inositols and female reproduction disorders: a consensus statement from the working group of the Club of the Italian Society of Endocrinology (SIE)-Women's Endocrinology. J Endocrinol Invest. 2024, 47:2111-41. 10.1007\/s40618-024-02363-w","journal-title":"J Endocrinol Invest"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.879271","article-title":"Bridging the gap: using consensus to explore entrustment decisions and feedback receptivity in competency-based emergency medicine residency programs through the construction of a Q-sample incorporating a Delphi technique","volume":"9","author":"Chang YC","year":"2022","unstructured":"Chang YC, Chuang RS, Hsiao CT, Khwepeya M, Nkambule NS. Bridging the gap: using consensus to explore entrustment decisions and feedback receptivity in competency-based emergency medicine residency programs through the construction of a Q-sample incorporating a Delphi technique. Front Med (Lausanne). 2022, 9:879271. 10.3389\/fmed.2022.879271","journal-title":"Front Med (Lausanne)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.5653\/cerm.2023.06485","article-title":"Systematic review of the roles of inositol and Vitamin D in improving fertility among patients with polycystic ovary syndrome","volume":"51","author":"Katyal G","year":"2024","unstructured":"Katyal G, Kaur G, Ashraf H, Bodapati A, Hanif A, Okafor DK, Khan S. Systematic review of the roles of inositol and Vitamin D in improving fertility among patients with polycystic ovary syndrome. Clin Exp Reprod Med. 2024, 51:181-91. 10.5653\/cerm.2023.06485","journal-title":"Clin Exp Reprod Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25235566","article-title":"Inositols in PCOS","volume":"25","author":"Kamenov Z","year":"2020","unstructured":"Kamenov Z, Gateva A. Inositols in PCOS. Molecules. 2020, 25:10.3390\/molecules25235566","journal-title":"Molecules"},{"key":"ref23","article-title":"Inositol for treating dermatological disorders: a systematic review","volume":"1","author":"Quach M","year":"2024","unstructured":"Quach M, Chang YF, Lee I, Tai L, Choi F, Bodemer A. Inositol for treating dermatological disorders: a systematic review. J Integrat Dermatol. 2024, 1:","journal-title":"J Integrat Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3204083","article-title":"A combined therapy with myo-inositol and D-chiro-Inositol improves endocrine parameters and insulin resistance in PCOS young overweight women","volume":"2016","author":"Benelli E","year":"2016","unstructured":"Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A combined therapy with myo-inositol and D-chiro-Inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol. 2016, 2016:3204083. 10.1155\/2016\/3204083","journal-title":"Int J Endocrinol"},{"key":"ref25","article-title":"The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone","volume":"16","author":"Nordio M","year":"2012","unstructured":"Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012, 16:575-81.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2023.2301554","article-title":"Update on the combination of myo-inositol\/d-chiro-inositol for the treatment of polycystic ovary syndrome","volume":"40","author":"Lete I","year":"2024","unstructured":"Lete I, Mart\u00ednez A, Lasaga I, Centuri\u00f3n E, Vesga A. Update on the combination of myo-inositol\/d-chiro-inositol for the treatment of polycystic ovary syndrome. Gynecol Endocrinol. 2024, 40:2301554. 10.1080\/09513590.2023.2301554","journal-title":"Gynecol Endocrinol"},{"key":"ref27","article-title":"Inositol for the Management of Polycystic Ovary Syndrome: SOGC Position Statement","author":"Antaki R","year":"2025","unstructured":"Antaki R, Desrosiers K, Francoeur D, Magee B, Mills K. Inositol for the Management of Polycystic Ovary Syndrome: SOGC Position Statement. Society of Obstetricians and Gynaecologists of Canada, Ottawa, ON; 2025."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.18203\/2320-1770.ijrcog20214648","article-title":"Role of oral inositol supplementation in women with polycystic ovarian syndrome","volume":"10","author":"Malik N","year":"2021","unstructured":"Malik N, Dubey N. Role of oral inositol supplementation in women with polycystic ovarian syndrome. Int J Reprod Contracept Obstet Gynecol. 2021, 10:4493-8. 10.18203\/2320-1770.ijrcog20214648","journal-title":"Int J Reprod Contracept Obstet Gynecol"},{"key":"ref29","article-title":"Role of myo-inositol in treatment of young females affected by polycystic ovarian syndrome: quasi experimental study","volume":"10","author":"Qamar H","year":"2020","unstructured":"Qamar H, Mustafa R. Role of myo-inositol in treatment of young females affected by polycystic ovarian syndrome: quasi experimental study. J Bahria Univ Med Dent Coll. 2020, 10:142-6.","journal-title":"J Bahria Univ Med Dent Coll"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12121183","article-title":"Myoinositol vs. metformin in women with polycystic ovary syndrome: a randomized controlled clinical trial","volume":"12","author":"Ravn P","year":"2022","unstructured":"Ravn P, Gram F, Andersen MS, Glintborg D. Myoinositol vs. metformin in women with polycystic ovary syndrome: a randomized controlled clinical trial. Metabolites. 2022, 12:10.3390\/metabo12121183","journal-title":"Metabolites"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.41748","article-title":"Myoinositol versus metformin in the treatment of polycystic ovarian syndrome: a systematic review","volume":"15","author":"Bodepudi R","year":"2023","unstructured":"Bodepudi R, Seher S, Khan SA, et al.. Myoinositol versus metformin in the treatment of polycystic ovarian syndrome: a systematic review. Cureus. 2023, 15:e41748. 10.7759\/cureus.41748","journal-title":"Cureus"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1979654","article-title":"Inositol treatment and ART outcomes in women with PCOS","volume":"2016","author":"Garg D","year":"2016","unstructured":"Garg D, Tal R. Inositol treatment and ART outcomes in women with PCOS. Int J Endocrinol. 2016, 2016:1979654. 10.1155\/2016\/1979654","journal-title":"Int J Endocrinol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00404-014-3552-6","article-title":"Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-chiro-inositol","volume":"291","author":"Lagan\u00e0 AS","year":"2015","unstructured":"Lagan\u00e0 AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-chiro-inositol. Arch Gynecol Obstet. 2015, 291:1181-6. 10.1007\/s00404-014-3552-6","journal-title":"Arch Gynecol Obstet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/490144-myo-inositol-for-cutaneous-manifestations-of-polycystic-ovary-syndrome-an-international-delphi-consensus-recommendation-for-dermatology-practice","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:44:13Z","timestamp":1782276253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/490144-myo-inositol-for-cutaneous-manifestations-of-polycystic-ovary-syndrome-an-international-delphi-consensus-recommendation-for-dermatology-practice"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.111393","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}